Cited by 229Chronic Kidney Disease and DiabetesBlood Pressure and Hypertension StudiesRenal and Vascular Pathologies

Effects of hypertension and dyslipidemia on the decline in renal function

Mänttäri, Matti, Tiula, Eero, Alikoski, Tiina, Manninen, Vesa·1995·Hypertension

Abstract

Experimental evidence suggests that in addition to hypertension, serum lipids might also accelerate the decline in renal function. We tested this hypothesis in 2702 dyslipidemic middle-aged men without renal disease participating in the Helsinki Heart Study, a coronary primary prevention trial. The decline in renal function was estimated from linear regression slopes based on reciprocals of 10 serum creatinine determinations over the study period. Renal function deteriorated 3% on average during the 5-year study, and hypertension accelerated this change. Subjects with an elevated ratio of low- to high-density lipoprotein cholesterol ( > 4.4) had a 20% faster decline than those with a ratio less than 3.2. Both the contribution of the lipoprotein ratio and the protective effect of high-density lipoprotein cholesterol alone remained significant in multiple regression analyses. In the study of joint effects the contribution of lipids was confined to subjects with simultaneous elevation of blood pressure and lipids. The results suggest that in addition to hypertension, blood lipids also modify the decline in renal function.

Integrity signals

Registry

Crossref · 10.1161/01.hyp.26.4.670

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Dyslipidemia is a risk factor for progressive kidney disease.

    “While dyslipidemia is a risk factor for progressive kidney disease (8,10,20,21)”

    From Effects of Fibrates in Kidney Disease (2012) · cites this paper as [21]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mänttäri, M., Tiula, E., Alikoski, T., & Manninen, V.
Affiliations
  • From the Department of Medicine, Helsinki (Finland) University Central Hospital.
  • Helsinki University Hospital (FI)
Venue
Hypertension
Published
1995-10
Volume
26
Issue
4
Pages
670-675
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
OpenAlex
W2131600514
Cited by
229
References
1
Citations by year
2026: 2 · 2025: 2 · 2024: 6 · 2023: 6 · 2022: 2 · 2021: 9 · 2020: 7 · 2019: 9 · 2018: 9 · 2017: 5 · 2016: 13 · 2015: 5 · 2014: 11 · 2013: 7 · 2012: 8
FWCI
1.07
Type
journal article
Language
en
Open access
closed
Locations
  • Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal and Vascular Pathologies
Keywords
dyslipidemia, renal function decline, serum creatinine, LDL cholesterol, HDL cholesterol, lipoprotein ratios, middle-aged men, Helsinki Heart Study
MeSH terms
Adult, Blood Pressure, Coronary Disease, Creatinine, Humans, Hyperlipidemias, Hypertension, Kidney, Lipids, Cholesterol, HDL, Cholesterol, LDL, Longitudinal Studies, Male, Middle Aged, Regression Analysis, Gemfibrozil, Cohort Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review